Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert I. Haddad, M.D.

Co-Author

This page shows the publications co-authored by Robert Haddad and Paul Busse.
Connection Strength

0.815
  1. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
    View in: PubMed
    Score: 0.083
  2. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
    View in: PubMed
    Score: 0.082
  3. Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
    View in: PubMed
    Score: 0.073
  4. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
    View in: PubMed
    Score: 0.066
  5. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
    View in: PubMed
    Score: 0.066
  6. NCCN GuidelinesĀ® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw. 2022 03; 20(3):224-234.
    View in: PubMed
    Score: 0.062
  7. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
    View in: PubMed
    Score: 0.056
  8. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 07; 18(7):873-898.
    View in: PubMed
    Score: 0.055
  9. NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018. J Natl Compr Canc Netw. 2018 05; 16(5):479-490.
    View in: PubMed
    Score: 0.047
  10. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 06; 15(6):761-770.
    View in: PubMed
    Score: 0.045
  11. Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7):847-55; quiz 856.
    View in: PubMed
    Score: 0.039
  12. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct; 12(10):1454-87.
    View in: PubMed
    Score: 0.037
  13. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Aug; 11(8):917-23.
    View in: PubMed
    Score: 0.034
  14. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
    View in: PubMed
    Score: 0.026
  15. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
    View in: PubMed
    Score: 0.025
  16. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.